This clinical trial is for men and women with B-cell Non-Hodgkin Lymphoma (NHL).
   
The purpose of this study is to study is to assess the safety and effectiveness of odronextamab in destroying participant's cancer cells. Odronextamab is an investigational drug, which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).
   
Odronextamab is a bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. It is given through a vein (intravenous [IV] infusion) or a central line.

All participants will receive infusions of the study drug that will take at least 1 hour and could take up to approximately 4 hours.
   
Participation length depends on how participants respond to the study drug.